Innovative chiral resolution using enantiospecific co-crystallization in solution

Crystal Growth and Design

Volumn 12, Issue 7, 2012, Pages 3374-3378

  Springuel, Géraldine ^a   Leyssens, Tom ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; CHIRAL CHROMATOGRAPHY; CHIRAL RESOLUTIONS; CO-CRYSTALS; COCRYSTALLIZATION; DIASTEREOMERIC; ENANTIOPURE; ENANTIOSPECIFIC; HYDROGEN BONDING INTERACTIONS; PRODUCTION PROCESS; RACEMIC MIXTURES; RESOLUTION TECHNIQUES; TERNARY PHASE DIAGRAMS;

ACETONITRILE; AMIDES; CHIRALITY; HYDROGEN BONDS; LIQUID CHROMATOGRAPHY; MIXTURES; ORGANIC ACIDS; PHASE DIAGRAMS; SALTS; STEREOCHEMISTRY;

ENANTIOMERS;

EID: 84863424946     PISSN: 15287483     EISSN: 15287505     Source Type: Journal    
DOI: 10.1021/cg300307z     Document Type: Article

References (34)

1. McConnell, O.; Bach II, A.; Balibar, C.; Byrne, N.; Cai, Y.; Carter, G.; Chlenov, M.; Di, L.; Fan, K.; Goljer, I.; He, Y.; Herold, D.; Kagan, M.; Kerns, E.; Koehn, F.; Kraml, C.; Marathias, V.; Marquez, B.; McDonald, L.; Nogle, L.; Petucci, C.; Schlingmann, G.; Tawa, G.; Tischler, M.; Williamson, R. T.; Sutherland, A.; Watts, W.; Young, M.; Zhang, M.-Y.; Zhang, Y.; Zhou, D.; Ho, D. Enantiomeric separation and determination of absolute stereochemistry of asymmetric molecules in drug discovery-Building chiral technology toolboxes Chirality 2007, 19 (9) 658-682
2. Stinson, S; Chiral, C. Pharmaceuticals Chem. Eng. News. 2001, 79 (40) 56-61
3. Lorenz, H.; Capla, F.; Polenske, D.; Elsner, M. P.; Seidel-Morgenstern, A. Crystallization based separation of enantiomers (review) J. Univ. Chem. Tech. Met. 2007, 42 (1) 5-16
4. Lyseng-Williamson, K. A. Levetiracetam: a review of its use in epilepsy Drugs 2011, 71 (4) 489-514
5. Fogassy, E.; Nógrádi, M.; Kozma, D.; Egri, G.; Pálovics, E.; Kiss, V. Optical resolution methods Org. Biomol. Chem. 2006, 4, 3011-3030
6. Kumar, V.; Malhotra, S. V. Ionic liquids as pharmaceutical salts: a historical perspective ACS Symp. Ser. 2010, 1038, 1-12
7. Neau, S. H. Pharmaceutical salts Water-Insoluble Drug Formulation 2000, 405-425
8. Srinivas, N. R. Evaluation of experimental strategies for the development of chiral chromatographic methods based on diastereomer formation Biomed. Chromatogr. 2004, 18 (4) 207-233
9. Chankvetadze, B. Recent trends in enantioseparation of chiral drugs. In Molecular Biology in Medicinal Chemistry, Book Series: Methods and Principles in Medicinal Chemistry; Dingermann, T.; Steinhilber, D.; Folkers, G., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: New York, 2004; Chapter 21, pp 181-210.
10. Wu, J.; Liu, P.; Wang, Q.; Chen, H.; Gao, P.; Wang, L.; Zhang, S. Investigation of enantiomeric separation of chiral drugs by CE using Cu(II)-clindamycin complex as a novel chiral selector Chromatographia 2011, 74, 789-797
11. Ward, T. J. Chiral separations Anal. Chem. 2002, 74, 2863-2872
12. Blaschke, G.; Chankvetadze, B. Resolution of Enantiomers of Chiral Drugs. In New Trends in Synthetic Medicinal Chemistry, Book Series: Methods and Principles in Medicinal Chemistry; Gualtieri, F., Eds.; Wiley-VCH Verlag GmbH: New York, 2008; Chapter 6, pp 139-173.
13. Herman, C.; Leyssens, T.; Vermylen, V.; Halloin, V.; Haut, B. Towards an accurate and precise determination of the solid-solid transition temperature of enantropic systems J. Chem. Thermodyn. 2011, 43 (5) 677-682
14. Herman, C.; Haut, B.; Halloin, V.; Vermylen, V.; Leyssens, T. Towards the determination of the thermodynamic and the metastable solubilities of the two morphs of enantiotropically related polymorphic systems: application to Etiracetam in methanol Org. Process Res. Dev. 2011, 15 (4) 774-782
15. Herman, C.; Leyssens, T.; Debaste, F.; Haut, B. Detection of the II-I etiracetam solvent-mediated polymorphic transformation through the online monitoring of the suspension apparent viscosity J. Cryst. Growth 2012, 342, 57-64
16. Herman, C.; Leyssens, T.; Vermylen, V.; Halloin, V.; Haut, B. A new approach for the estimation of the melting enthalpy of metastable crystalline compounds using differential scanning calorimetry J. Therm. Anal. Calorim. 2012, 107, 777-788
17. Herman, C.; Haut, B.; Douieb, S.; Larcy, A.; Vermylen, V.; Leyssens, T. Use of in situ Raman, FBRM and ATR-FTIR probes for the understanding of the solvent-mediated polymorphic transformation of II-I etiracetam in methanol Org. Process Res. Dev 2012, 16 (1) 49-56
18. Sekhon, B. S. Pharmaceutical co-crystals - A review Ars Pharm. 2009, 50 (3) 99-117
19. Hurtado, B.; Koepp, M. J.; Sander, J. W.; Thompson, P. J. The impact of levetiracetam on challenging behavior Epilepsy Behav. 2006, 8, 588
20. Isoherranen, N.; Yagen, B.; Soback, S.; Roeder, M.; Schurig, V.; Bialer, M. Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo- pyrrolidine acetamide in dogs Epilepsia 2001, 42 (7) 825-830
21. Kotkar, S. P.; Sudalai, A. A short enantioselective synthesis of the antiepileptic agent, levetiracetam based on proline-catalyzed asymmetric α-aminooxylation Tetradron Lett. 2006, 47, 6813-6815
22. Springuel, G.; Norberg, B.; Robeyns, K.; Wouters, J.; Leyssens, T. Advances in pharmaceutical co-crystal screening: effective co-crystal screening through structural resemblance Cryst. Growth Des. 2012, 12 (1) 475-484
23. Vishweshwar, P.; McMahon, J. A.; Bis, J. A.; Zaworotko, M. J. Pharmaceutical co-crystals J. Pharm. Sci. 2006, 95 (3) 499-516
24. Viertelhaus, S.; Hilfiker, R.; Blatter, F. Piracetam co-crystals with OH-group functionalized carboxylic acids Cryst. Growth Des. 2009, 9 (5) 2220-2228
25. Sekhon, B. S. Enantioseparation of chiral drugs - an overview Int. J. ChemTech Res. 2010, 2 (2) 1584-1594
26. Schultheiss, N.; Newman, A. Pharmaceutical cocrystals and their physicochemical properties Cryst. Growth Des. 2009, 9 (6) 2950-2967
27. Shan, N.; Zaworotko, M. J. The role of co-crystals in pharmaceutical sciences Drug Discovery Today 2008, 13, 440-446
28. Jones, W.; Motherwell, W. D. S.; Trask, A. V. Pharmaceutical co-crystals: an emerging approach to physical property enhancement MRS Bull. 2006, 31, 875-879
29. Cheney, M. L.; Shan, N.; Healey, E. R.; Hanna, M.; Wojtas, L.; Zaworotko, M. J.; Sava, V.; Song, S.; Sanchez-Ramos, J. R. Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine Cryst. Growth Des. 2010, 10 (1) 394-405
30. Thorey, P.; Bombicz, P.; Szilágyi, I. M.; Molnár, P.; Bánsághi, G.; Székely, E.; Simándi, B.; Párkányi, L.; Pokol, G.; Madarász, J. Co-crystal of (R, R)-1,2-cylohexanediol with (R, R)-tartaric acid, a key structure in resolution of the (±)-trans-diol by supercritical extraction, and the related ternary phase system Thermochim. Acta 2010, 497, 129-136
31. Brittain, H. G. Vibrational spectroscopic studies of cocrystals and salts. 4. Cocrystal products formed by benzylamine, α-methylbenzylamine, and their chloride salts Cryst. Growth Des. 2011, 11, 2500-2509
32. Chen, S.; Xi, H.; Henry, R. F.; Marsden, I.; Zhang, G.G.Z.. Chiral cocrystal solid solution: structures, melting point phase diagram, and chiral enrichment of (ibuprofen)2(4,4-dipyridyl) CrystEngComm 2010, 12, 1485-1493
33. Srisanga, S.; ter Horst, J. H. Racemic compound, conglomerate, or solid solution: phase diagram screening of chiral compounds Cryst. Growth Des. 2010, 10 (4) 1808-1812
34. Leyssens, T.; Springuel, G.; Montis, R.; Candoni, N.; Veesler, S. Importance of solvent selection for stoichiometrically diverse cocrystal systems: caffeine/maleic acid 1:1 and 2:1 cocrystals Cryst. Growth Des. 2012, 12, 1520-1530